ARGENX SE

Argenx SE is a Dutch European public company with limited liability, focused on the discovery, development, and commercialization of antibody-based therapies for severe autoimmune diseases. The company's core business model revolves around its Immunology Innovation Program (IIP), which leverages the llama immune system and proprietary antibody engineering technologies like SIMPLE ANTIBODY™, NHANCE™, and ABDEG™ to generate novel product candidates. Revenue is primarily generated from product net sales of its approved therapies, supplemented by collaboration revenue, research and development tax incentives, and payroll tax rebates. The company aims to treat 50,000 patients globally, secure 10 labeled indications, and advance five pipeline candidates into Phase 3 development by 2030 ¹.

The company's flagship product, VYVGART (efgartigimod alfa-fcab), is an immunoglobulin G (IgG) Fc-antibody fragment that targets the FcRn receptor, reducing pathogenic IgG antibodies. VYVGART is approved in over 30 countries across three indications: generalized myasthenia gravis (gMG), chronic inflammatory demyelinating polyneuropathy (CIDP), and immune thrombocytopenia (ITP) in Japan only ². It is available in intravenous (IV), subcutaneous (SC), and prefilled syringe (PFS) formulations, with the PFS enabling self-injection for adult gMG and CIDP patients in the U.S. ³.

For the fiscal year ended December 31, 2025, Argenx reported product net sales of $4.151 billion ⁴, a significant increase from $2.186 billion in 2024 ⁵. Total operating income for 2025 was $4.248 billion ⁶, up from $2.252 billion in 2024 ⁷. Cost of sales increased to $450.665 million in 2025 from $227.289 million in 2024 ⁸. Research and development expenses rose to $1.364 billion in 2025 from $983.423 million in 2024 ⁹, while selling, general and administrative expenses increased to $1.367 billion in 2025 from $1.055 billion in 2024 ¹⁰. The company achieved an operating profit of $1.054 billion in 2025, a substantial improvement from an operating loss of $21.654 million in 2024 ¹¹. Net income for 2025 was $1.292 billion ¹², compared to $833.040 million in 2024 ¹³. Diluted EPS for 2025 was $19.57 ¹⁴, up from $12.78 in 2024 ¹⁵.

The company's financial position strengthened, with cash and cash equivalents increasing to $3.5 billion as of December 31, 2025, from $1.5 billion as of December 31, 2024 ¹⁶. Current financial assets were $0.9 billion in 2025, down from $1.9 billion in 2024 ¹⁷. Total assets reached $8.7 billion as of December 31, 2025, compared to $6.2 billion in 2024 ¹⁸. The company reported accumulated losses of $0.3 billion as of December 31, 2025 ¹⁹.

During 2025, Argenx made significant operational strides, including the successful launch of the VYVGART Hytrulo pre-filled syringe in the U.S. in April, followed by the EU and Japan ²⁰. Positive topline data from the ADAPT-SERON clinical trial in anti-AChR antibody-negative gMG were reported, leading to a supplemental BLA filing in December 2025, which was accepted for priority review with an expected PDUFA date of May 10, 2026 ²¹. Additionally, positive data from the ADAPT OCULUS clinical trial in ocular MG were reported in February 2026 ²². The company also expanded its manufacturing partnership with Fujifilm to include a new site in North Carolina, U.S. ²³.

Argenx's 2026 outlook is centered on three strategic priorities: impacting more patients globally with VYVGART, shaping the long-term future of FcRn medicines, and delivering the next wave of immunology innovation ²⁴. The company aims to drive broader adoption of VYVGART across current patient populations and unlock new opportunities through potential label expansions ²⁵.

A key growth area for Argenx is the expansion of VYVGART's indications. The company expects topline results in the first quarter of 2026 for Ocular MG (ADAPT OCULUS) with efgartigimod ²⁶. Furthermore, topline results are anticipated in the third quarter of 2026 from the ALKIVIA clinical trial evaluating three myositis subsets (IMNM, ASyS, and DM) with efgartigimod ²⁷. The ADVANCE-NEXT Phase 3 clinical trial for primary ITP with efgartigimod is expected to deliver topline results in the fourth quarter of 2026 ²⁸. These potential label expansions are crucial for increasing VYVGART's patient reach and commercial potential.

Another significant growth vector is the advancement of empasiprubart, a first-in-class antibody targeting complement C2. Topline results from the EMPASSION clinical trial in MMN are expected in the fourth quarter of 2026 ²⁹. Additionally, topline results from both the EMVIGORATE and EMNERGIZE clinical trials for empasiprubart in CIDP are expected in the second half of 2027 ³⁰. The company also plans to initiate a Phase 3 clinical trial for adimanebart in CMS in the third quarter of 2026, following positive Phase 1b results ³¹. These programs are designed to establish new standards of care in immune-mediated neuromuscular diseases and diversify the company's product portfolio.

Operationally, Argenx anticipates that its operating expenses will continue to increase as it executes registrational and proof-of-concept studies across efgartigimod, empasiprubart, and adimanebart, and continues to invest in its IIP ³². The company also expects increased costs related to the maintenance, expansion, and protection of its intellectual property portfolio, including litigation costs ³³. Costs of development and commercialization may also rise due to current and future collaborations ³⁴.

Regarding capital allocation, Argenx expects its existing cash and cash equivalents and current financial assets to fund operating expenses and capital expenditure requirements through at least the next twelve months ³⁵. The company has no ongoing material financing commitments, such as lines of credit or guarantees, that are expected to affect liquidity over the next five years, other than leases and operational commitments ³⁶. Capital expenditure in 2026 is anticipated to be financed from cash flows from operating activities and cash reserves ³⁷.

Argenx faces several material risks, including the commercial success of its products and product candidates being dependent on market acceptance, which can be impacted by negative publicity, narrow approvals, and competition ³⁸. The pharmaceutical market is highly competitive, with numerous companies developing competing therapies, including biosimilars, which could erode sales or force price reductions ³⁹. Enacted and future legislation, such as the U.S. Inflation Reduction Act (IRA), could significantly reduce prices, increase rebate obligations, and affect coverage and demand for products ⁴⁰. The company is subject to government pricing laws and regulations, and non-compliance could lead to substantial fines and penalties ⁴¹. Failure to obtain or maintain adequate pricing, coverage, or reimbursement status for its products, especially for orphan drug indications, could limit revenue generation ⁴². Reliance on third parties for research, manufacturing, and clinical trials exposes the company to risks of delays, increased costs, and non-compliance ⁴³. Disruptions in the supply chain due to reliance on single-source suppliers for raw materials or issues with contract manufacturing organizations (CMOs) could lead to shortages and impact revenue potential ⁴⁴. The company is also exposed to product liability claims, which could be costly to defend and damage its reputation ⁴⁵. Cybersecurity threats and evolving privacy and AI regulations, such as the GDPR and AI Act, pose risks of system failures, data breaches, and significant penalties for non-compliance ⁴⁶. Geopolitical threats and macroeconomic uncertainties, including trade disputes and tariffs, could adversely affect business and financial performance, particularly given the company's international operations and clinical trials across multiple jurisdictions ⁴⁷. For example, the BIOSECURE Act in the U.S. could restrict the company's ability to collaborate with certain Chinese biotechnology companies ⁴⁸.

Management's message to shareholders emphasizes a year of strong execution and strategic delivery, advancing the company's Vision 2030 ambition to reach 50,000 patients globally, secure 10 labeled indications, and advance five pipeline candidates into Phase 3 development by 2030 ⁴⁹. They highlighted the successful launch of the VYVGART Hytrulo pre-filled syringe, which expanded access and convenience for patients, and the achievement of VYVGART surpassing $1 billion in product net sales in a single quarter for the first time in the third quarter of 2025 ⁵⁰. Management also pointed to positive topline results from the ADAPT SERON clinical trial in Seronegative gMG, reinforcing the broad applicability of VYVGART and supporting a supplemental BLA filing with an expected PDUFA date of May 10, 2026 ⁵¹. The three strategic priorities for 2026 are to impact more patients globally with VYVGART, shape the long-term future of FcRn medicines, and deliver the next wave of immunology innovation ⁵². The company anticipates delivering results on four registrational readouts in 2026 and two more in 2027, including topline results for Ocular MG (ADAPT OCULUS) in the first quarter of 2026, ALKIVIA clinical trial (Myositis) in the third quarter of 2026, EMPASSION clinical trial (MMN) in the fourth quarter of 2026, and primary ITP (ADVANCE-NEXT) in the fourth quarter of 2026 ⁵³. Management also announced a leadership transition, with Karen Massey, current COO, expected to become CEO and Executive Director, and Tim Van Hauwermeiren, current CEO, transitioning to Non-Executive Chairperson of the Board of Directors, both subject to shareholder approval at the 2026 General Meeting ⁵⁴.